MCID: ORL012
MIFTS: 46

Oral Leukoplakia malady

Categories: Rare diseases, Oral diseases

Aliases & Classifications for Oral Leukoplakia

Aliases & Descriptions for Oral Leukoplakia:

Name: Oral Leukoplakia 50 29
Leukoplakia, Oral 69
Leukoplakia Oral 52

Classifications:



Summaries for Oral Leukoplakia

NIH Rare Diseases : 50 oral leukoplakia describes a white plaque that does not rub off and cannot be characterized as any other condition. though it may occur in any part of the mouth, it generally affects the tongue, gums, and inner cheek. physicians will usually biopsy oral leukoplakia lesions as 20-40% of cases are precancerous or cancerous at the time of biopsy and another 8-15% become cancerous over time. the exact cause of oral leukoplakia is not known. factors that may increase the risk of developing oral leukoplakia include smoking, alcohol use, vitamin deficiencies, malocclusion, and a weakened immune system.treatment depends on the biopsy results and the size, appearance, and location of the oral leukoplakia. removal or ablation of the lesion by surgery, laser, or cryotherapy (use of low temperature) may be recommended. last updated: 6/12/2015

MalaCards based summary : Oral Leukoplakia, also known as leukoplakia, oral, is related to oral hairy leukoplakia and dyskeratosis congenita, and has symptoms including enanthema and oral mucosal blisters. An important gene associated with Oral Leukoplakia is GSTM1 (Glutathione S-Transferase Mu 1), and among its related pathways/superpathways are Cell Cycle, Mitotic and Glioma. The drugs Aminolevulinic acid and Dermatologic Agents have been mentioned in the context of this disorder. Affiliated tissues include tongue, testes and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and endocrine/exocrine gland

Related Diseases for Oral Leukoplakia

Diseases related to Oral Leukoplakia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
id Related Disease Score Top Affiliating Genes
1 oral hairy leukoplakia 11.5
2 dyskeratosis congenita 11.0
3 oral mucosa leukoplakia 11.0
4 leukoplakia 11.0
5 pachyonychia congenita 3 10.9
6 pachyonychia congenita 4 10.9
7 revesz syndrome 10.9
8 dyskeratosis congenita, autosomal recessive 6 10.9
9 dyskeratosis congenita, autosomal dominant 6 10.9
10 pachyonychia congenita 1 10.9
11 pachyonychia congenita 2 10.9
12 dyskeratosis congenita, autosomal recessive 5 10.9
13 squamous cell carcinoma 10.5
14 oral squamous cell carcinoma 10.4
15 wolffian adnexal neoplasm 10.3 MKI67 TP53
16 clear cell adenofibroma 10.3 CDKN2A TP53
17 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
18 lacrimal gland squamous cell carcinoma 10.2 CDKN2A TP53
19 lichen planus 10.2
20 endometrial squamous cell carcinoma 10.2 CDKN2A TP53
21 ampulla of vater neoplasm 10.2 CDKN2A TP53
22 coccidiosis 10.2 CDKN2A TP53
23 postpoliomyelitis syndrome 10.2 CDKN2A TP53
24 paraphimosis 10.2 CDKN2A TP53
25 anal carcinoma in situ 10.2 CDKN2A TP53
26 uterine disease 10.2 CDKN2A TP53
27 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A TP53
28 spastic ataxia 5 10.2 CDKN2A TP53
29 gallbladder pleomorphic giant cell adenocarcinoma 10.2 CDKN2A TP53
30 villoglandular endometrial endometrioid adenocarcinoma 10.2 CCND1 TP53
31 adult epithelioid sarcoma 10.2 CDKN2A TP53
32 aml with myelodysplasia-related features 10.2 CDKN2A MKI67
33 bladder adenocarcinoma 10.2 CDKN2A MKI67
34 uterine cervix leukoplakia 10.2 CDKN2A TP53
35 spastic paraplegia 1 10.2 MKI67 TP53
36 house allergic alveolitis 10.2 CDKN2A TP53
37 cystinosis, nephropathic 10.2 ERBB2 TP53
38 lung clear cell-sugar-tumor 10.2 ERBB2 TP53
39 oral submucous fibrosis 10.2
40 childhood brain stem glioma 10.2 CCND1 TP53
41 urethral verrucous carcinoma 10.2 CDKN2A TP53
42 brachydactyly tibial hypoplasia 10.2 CCND1 CDKN2A
43 bronchiolitis obliterans with obstructive pulmonary disease 10.2 CCND1 MKI67
44 decubitus ulcer 10.2 CCND1 CDKN2A
45 central nervous system mature teratoma 10.2 ERBB2 TP53
46 anal neuroendocrine tumor 10.2 CCND1 CDKN2A
47 chronic monocytic leukemia 10.2 CDKN2A TP53
48 active vestibular meniere's disease 10.1 CCND1 CDKN2A
49 episodic ataxia 10.1 CCND1 CDKN2A
50 oral cancer 10.1

Graphical network of the top 20 diseases related to Oral Leukoplakia:



Diseases related to Oral Leukoplakia

Symptoms & Phenotypes for Oral Leukoplakia

UMLS symptoms related to Oral Leukoplakia:


enanthema, oral mucosal blisters

GenomeRNAi Phenotypes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 XRCC1 CDKN2A PCNA TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 CCND1 CDKN2A PCNA TP53 XRCC1
3 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.13 CCND1 MKI67 PCNA

MGI Mouse Phenotypes related to Oral Leukoplakia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 CCND1 CDKN2A ERBB2 PCNA TINF2 TP53
2 growth/size/body region MP:0005378 9.8 CCND1 CDKN2A ERBB2 PCNA TINF2 TP53
3 neoplasm MP:0002006 9.55 CCND1 CDKN2A ERBB2 TP53 XRCC1
4 normal MP:0002873 9.43 CCND1 ERBB2 MKI67 TINF2 TP53 XRCC1
5 reproductive system MP:0005389 9.1 CCND1 CDKN2A ERBB2 PCNA TINF2 TP53

Drugs & Therapeutics for Oral Leukoplakia

Drugs for Oral Leukoplakia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2 106-60-5 137
2 Dermatologic Agents Phase 3,Phase 1,Phase 2
3 Photosensitizing Agents Phase 3,Phase 1,Phase 2
4
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
5
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
6
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
7
Trioxsalen Approved Phase 2 3902-71-4 5585
8
Ketorolac Approved Phase 2 74103-06-3, 66635-83-4 3826
9
Metformin Approved Phase 2 657-24-9 14219 4091
10
Maleic acid Experimental Phase 2 110-16-7 444266
11
Fenretinide Investigational Phase 2 65646-68-6
12 Analgesics Phase 2,Phase 1
13 Analgesics, Non-Narcotic Phase 2,Phase 1
14 Anti-Inflammatory Agents Phase 2,Phase 1
15 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1
16 Antirheumatic Agents Phase 2,Phase 1
17 Cyclooxygenase 2 Inhibitors Phase 2
18 Cyclooxygenase Inhibitors Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 2,Phase 1
20 Hypoglycemic Agents Phase 2
21 Retinamide Phase 2
22 Pharmaceutical Solutions Phase 1, Phase 2
23 Dihematoporphyrin Ether Phase 2
24 Ether Phase 2
25 Hematoporphyrin Derivative Phase 2
26 Hematoporphyrins Phase 2
27 Ketorolac Tromethamine Phase 2
28 Tea Nutraceutical Phase 2
29
Aspirin Approved, Vet_approved Phase 1 50-78-2 2244
30 Antipyretics Phase 1
31 Fibrinolytic Agents Phase 1
32 Platelet Aggregation Inhibitors Phase 1
33
Heparin Approved, Investigational 9005-49-6 772 46507594
34
Dapsone Approved, Investigational 80-08-0 2955
35
Nicotine Approved 54-11-5 942 89594
36
Sulindac Approved 38194-50-2 5352 1548887
37
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
38
leucovorin Approved, Nutraceutical 58-05-9 54575, 6560146 143
39 calcium heparin
40 Coagulants
41 Hemostatics
42 Tolonium Chloride
43 Acyclovir
44 Anti-Infective Agents
45 Antiviral Agents
46 Anti-Bacterial Agents
47 Antimalarials
48 Antiparasitic Agents
49 Antiprotozoal Agents
50 Folic Acid Antagonists

Interventional clinical trials:

(show all 31)
id Name Status NCT ID Phase
1 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
2 Photodynamic Therapy for Oral Precursor Lesions Completed NCT01497951 Phase 3
3 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Unknown status NCT00052611 Phase 2
4 Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Completed NCT00369174 Phase 2
5 Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00099021 Phase 2
6 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2
7 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2
8 Fenretinide in Treating Patients With Leukoplakia of the Mouth Completed NCT00004161 Phase 2
9 Treatment of Oral Premalignant Lesions With 5-ALA PDT Completed NCT00571974 Phase 1, Phase 2
10 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract Completed NCT00453336 Phase 2
11 Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR Completed NCT00001698 Phase 2
12 Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Recruiting NCT02581137 Phase 2
13 A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Terminated NCT00176566 Phase 2
14 Pioglitazone for Oral Premalignant Lesions Terminated NCT00951379 Phase 2
15 Aspirin Mouthwash in Treating Patients With Oral Leukoplakia Completed NCT01238185 Phase 1
16 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Terminated NCT00571558 Phase 1
17 Least Invasive Nonlinear Light Microscopy Unknown status NCT00767442
18 Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity Unknown status NCT01636544
19 Biomarkers for Oral Cancer Completed NCT00341497
20 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy Completed NCT03031899
21 Clinical Research Core Dental Screening Protocol Completed NCT00090818
22 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia Completed NCT00835341
23 Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV) Completed NCT00002026
24 Natural History of Oro-pharyngeal Cancer Precursors Completed NCT00179361
25 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
26 Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions Completed NCT02323672
27 Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) Completed NCT00002043
28 A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery Recruiting NCT01355926
29 Tobacco Cessation Intervention Study for Oral Diseases Recruiting NCT02737176
30 Fluorescence & Reflectance Imaging to Detect Oral Neoplasia Recruiting NCT00542373
31 A Randomized Study of Sulindac in Oral Premalignant Lesions Active, not recruiting NCT00299195

Search NIH Clinical Center for Oral Leukoplakia

Genetic Tests for Oral Leukoplakia

Genetic tests related to Oral Leukoplakia:

id Genetic test Affiliating Genes
1 Oral Leukoplakia 29

Anatomical Context for Oral Leukoplakia

MalaCards organs/tissues related to Oral Leukoplakia:

39
Tongue, Testes, Liver, T Cells, Colon, Breast

Publications for Oral Leukoplakia

Articles related to Oral Leukoplakia:

(show top 50) (show all 502)
id Title Authors Year
1
Association between smoking, glycemia, blood lipoproteins, and risk of oral leukoplakia. ( 27219072 )
2016
2
High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genes. ( 27255271 )
2016
3
Signal regulatory protein I+ associated with the progression of oral leukoplakia and oral squamous cell carcinoma regulates phenotype switch of macrophages. ( 27793032 )
2016
4
A study of Ki-67 expression and its clinicopathological determinants in nondysplastic oral leukoplakia. ( 27994417 )
2016
5
p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia. ( 27605086 )
2016
6
MicroRNAs-208b-3p, 204-5p, 129-2-3p and 3065-5p as predictive markers of oral leukoplakia that progress to cancer. ( 27508095 )
2016
7
Web-based information on the treatment of oral leukoplakia - quality and readability. ( 27233229 )
2016
8
Interventions for treating oral leukoplakia to prevent oral cancer. ( 27471845 )
2016
9
Genetic Abnormalities in Oral Leukoplakia and Oral Cancer Progression. ( 27356725 )
2016
10
Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population. ( 27721611 )
2016
11
Oral Leukoplakia: Clinicopathological Correlation and Its Relevance to Regional Tobacco-related Habit Index. ( 27595730 )
2016
12
Candida infection in oral leukoplakia: an unperceived public health problem. ( 27538681 )
2016
13
Immunohistochemical Expression of Podoplanin in Clinical Variants of Oral Leukoplakia and Its Correlation With Epithelial Dysplasia. ( 27153448 )
2016
14
A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia. ( 27267893 )
2016
15
Prevalence of Carcinomatous Foci in Oral Leukoplakia: A Clinicopathologic Study of 546 Indian Samples. ( 27656569 )
2016
16
Changes in the salivary microbiota of oral leukoplakia and oral cancer. ( 27026576 )
2016
17
Immunohistochemical Study of TGF-I^1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma: Correlations Between Clinicopathologic Factors and Overall Survival. ( 26990749 )
2016
18
A proteomic approach to compare saliva from individuals with and without oral leukoplakia. ( 27478070 )
2016
19
Salivary mRNA markers having the potential to detect oral squamous cell carcinoma segregated from oral leukoplakia with dysplasia. ( 27263493 )
2016
20
GSTM1 null polymorphism prevalence in tobacco users, oral leukoplakia and oral squamous cell carcinoma patients in South Indian population: A polymerase chain reaction study. ( 27723629 )
2016
21
Oral leukoplakia associated with amalgam restorations. ( 27665986 )
2016
22
Oral leukoplakia treatment with the carbon dioxide laser: A systematic review of the literature. ( 26920045 )
2016
23
Vascular alterations after photodynamic therapy mediated by 5-aminolevulinic acid in oral leukoplakia. ( 28004205 )
2016
24
Associations Among Glutathione S-Transferase T1, M1, and P1 Polymorphisms and the Risk of Oral Leukoplakia. ( 27152506 )
2016
25
Semi-quantifiable angiogenesis parameters in association with the malignant transformation of oral leukoplakia. ( 28036153 )
2016
26
Role of human papilloma virus in oral leukoplakia. ( 27146781 )
2016
27
Computer aided morphometric analysis of oral leukoplakia and oral squamous cell carcinoma. ( 26983454 )
2016
28
Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma. ( 27225603 )
2016
29
Reduced CX3CL1 Secretion Contributes to the Susceptibility of Oral Leukoplakia-Associated Fibroblasts to Candida albicans. ( 27891323 )
2016
30
Oral leukoplakia - To treat or not to treat. ( 26785709 )
2016
31
Aberrant DKK3 expression in the oral leukoplakia and oral submucous fibrosis: a comparative immunohistochemical study. ( 27349317 )
2016
32
Comparative cytomorphometric analysis of oral mucosal cells in normal, tobacco users, oral leukoplakia and oral squamous cell carcinoma. ( 26811574 )
2015
33
A histochemical comparison of methyl green-pyronin, and hematoxylin and eosin for detecting apoptotic cells in oral squamous cell carcinoma, oral leukoplakia, oral submucous fibrosis and normal oral mucosa. ( 25539051 )
2015
34
Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis. ( 26339574 )
2015
35
Efficacy of argyrophilic nucleolar organizing region analysis using computer-assisted and manual in oral leukoplakia: A comparative study. ( 26837981 )
2015
36
Impairment of mesenchymal stem cells derived from oral leukoplakia. ( 26617710 )
2015
37
Peroxiredoxin 1 suppresses apoptosis via regulation of the apoptosis signal-regulating kinase 1 signaling pathway in human oral leukoplakia. ( 26622762 )
2015
38
Comparison of Immunohistochemical Expression of Antiapoptotic Protein Survivin in Normal Oral Mucosa, Oral Leukoplakia, and Oral Squamous Cell Carcinoma. ( 26457223 )
2015
39
The treatment of oral leukoplakia with the CO2 laser: A retrospective study of 65 patients. ( 25913630 )
2015
40
Oral leukoplakia, the ongoing discussion on definition and terminology. ( 26449439 )
2015
41
Predictive Role of p53 Protein as a Single Marker or Associated with ki67 Antigen in Oral Leukoplakia: A Retrospective Longitudinal Study. ( 25674170 )
2015
42
Margins of oral leukoplakia: autofluorescence and histopathology. ( 25434724 )
2015
43
Estimation of oral leukoplakia treatment records in the research of the Department of Maxillofacial and Oral Surgery, Medical University of Gdansk. ( 26015781 )
2015
44
Association between histopathological features of dysplasia in oral leukoplakia and loss of heterozygosity. ( 26042642 )
2015
45
Oral leukoplakia in patients with Fanconi anaemia without hematopoietic stem cell transplantation. ( 25682760 )
2015
46
Malignant transformation of oral leukoplakia: a systematic review of observational studies. ( 26189354 )
2015
47
Marked variation in malignant transformation rates of oral leukoplakia. ( 26680515 )
2015
48
Inter- and intra-lesional molecular heterogeneity of oral leukoplakia. ( 25467776 )
2015
49
Fourier-transform-infrared-spectroscopy based spectral-biomarker selection towards optimum diagnostic differentiation of oral leukoplakia and cancer. ( 26342309 )
2015
50
Tobacco use and oral leukoplakia: cross-sectional study among the Gond tribe in Madhya Pradesh. ( 25743823 )
2015

Variations for Oral Leukoplakia

Expression for Oral Leukoplakia

Search GEO for disease gene expression data for Oral Leukoplakia.

Pathways for Oral Leukoplakia

Pathways related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 35)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 CCND1 CDKN2A PCNA TINF2 TP53
2
Show member pathways
12.83 CCND1 CDKN2A ERBB2 TP53
3 12.48 CCND1 CDKN2A ERBB2 TP53
4
Show member pathways
12.47 CCND1 PCNA TP53 XRCC1
5
Show member pathways
12.37 CCND1 CDKN2A PCNA TP53
6 12.3 CCND1 CDKN2A ERBB2 TP53
7 12.22 CCND1 CDKN2A PCNA TP53
8
Show member pathways
12.21 CCND1 PCNA TP53
9
Show member pathways
12.19 CCND1 CDKN2A TP53
10
Show member pathways
12.17 CCND1 CDKN2A TP53
11 12.16 CCND1 CDKN2A PCNA TP53
12
Show member pathways
12.13 CCND1 ERBB2 TP53
13
Show member pathways
12.13 CCND1 ERBB2 PCNA TP53
14 12.11 CCND1 ERBB2 TP53
15 12.1 CCND1 CDKN2A TP53
16 12 CCND1 ERBB2 PCNA
17
Show member pathways
11.98 CCND1 ERBB2 TP53
18
Show member pathways
11.82 CCND1 CDKN2A ERBB2 TP53
19 11.8 CCND1 CDKN2A TP53
20 11.77 CDKN2A PCNA TP53
21 11.75 CCND1 CDKN2A PCNA TP53
22 11.66 CCND1 PCNA TP53
23 11.62 CCND1 CDKN2A ERBB2 TP53
24 11.57 CCND1 CDKN2A MKI67 PCNA TP53 XRCC1
25 11.34 CCND1 CDKN2A TP53
26 11.32 CCND1 CDKN2A ERBB2 TP53
27 11.25 CCND1 PCNA TP53
28 11.23 CCND1 XRCC1
29 11.15 CDKN2A TP53
30 11.12 CDKN2A ERBB2 GSTM1 TP53
31 11.1 PCNA TP53
32 11.09 CCND1 TP53
33 11.09 CCND1 PCNA TP53
34 10.95 CDKN2A TP53
35
Show member pathways
10.95 CDKN2A TP53

GO Terms for Oral Leukoplakia

Cellular components related to Oral Leukoplakia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 9.16 PCNA TP53
2 nuclear chromosome, telomeric region GO:0000784 9.13 PCNA TINF2 XRCC1
3 nuclear body GO:0016604 8.92 MKI67 PCNA TINF2 TP53

Biological processes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.76 CCND1 CDKN2A MKI67 TP53
2 cellular response to DNA damage stimulus GO:0006974 9.67 CCND1 PCNA TP53 XRCC1
3 base-excision repair GO:0006284 9.49 TP53 XRCC1
4 liver regeneration GO:0097421 9.48 CCND1 PCNA
5 cell proliferation GO:0008283 9.46 ERBB2 MKI67 PCNA TP53
6 nucleotide-excision repair, DNA gap filling GO:0006297 9.43 PCNA XRCC1
7 response to X-ray GO:0010165 9.4 CCND1 TP53
8 negative regulation of telomerase activity GO:0051974 9.32 TINF2 TP53
9 replicative senescence GO:0090399 9.26 CDKN2A TP53
10 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
11 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 CDKN2A ERBB2

Molecular functions related to Oral Leukoplakia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 histone acetyltransferase binding GO:0035035 9.16 PCNA TP53
2 damaged DNA binding GO:0003684 9.13 PCNA TP53 XRCC1
3 enzyme binding GO:0019899 9.02 CCND1 GSTM1 PCNA TP53 XRCC1

Sources for Oral Leukoplakia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....